Addiction Medicine Updates

Videos

UPDATES

OPIOIDS

SBIRT

TRAINING EVENTS

Latest News & Upcoming Events

North Carolina Statewide Overdose Surveillance Reports

North Carolina Statewide Overdose Surveillance Reports

Learn more about overdoses in North Carolina with the resources available through the Injury and Violence Prevention Branch of the Division of Public Health. The Statewide Overdose Surveillance Reports provide annual or monthly statewide summaries plus county specific...

No Shortcuts to Safer Opioid Prescribing

No Shortcuts to Safer Opioid Prescribing

In a New England Journal of Medicine article, authors Deborah Dowell, MD, MPH, Tamara Haegerich, PhD., and Roger Chou, MD discuss the Guideline for Prescribing Opioids for Chronic Pain released by the Centers for Disease Control and Prevention (CDC) 2016,1 Medical and...

May
27
Mon
Waiver Training Online PCSS Office-Based Treatment for Opioid Use Disorders Webinar @ Live Webcast
May 27 @ 5:00 pm – 9:15 pm

As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine. 

Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

For More Information and FREE training and educational resources on Medication Assisted Treatment –Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT) visit www.pcssnow.org.

PCSS is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with the: American Osteopathic Academy of Addiction Medicine (AOAAM); Addiction Technology Transfer Center (ATTC); American Academy of Family Physicians (AAFP); American Academy of Neurology (AAN); American Academy of Pain Medicine (AAPM); American Academy of Pediatrics (AAP); American College of Emergency Physicians (ACEP); American College of Physicians (ACP); American Dental Association (ADA); American Medical Association (AMA); American Psychiatric Association (APA); American Psychiatric Nurses Association (APNA); American Society of Addiction Medicine (ASAM); American Society for Pain Management Nursing (ASPMN); Association for Medical Education and Research in Substance Abuse (AMERSA); International Nurses Society on Addictions (IntNSA); National Association of Community Health Centers (NACHC); National Association of Drug Court Professionals (NADCP), and the Southeast Consortium for Substance Abuse Training (SECSAT). 

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

May
28
Tue
Vaccines for Opioid Use Disorder: Focusing on the Fentanyl Epidemic @ Webinar
May 28 @ 12:00 pm – 1:00 pm

Presenter(s): Thomas R. Kosten, MD, Waggoner Professor in Psychiatry, Pharmacology, Neuroscience, Baylor College of Medicine; Fang Yang, MD, PhD, Addiction Psychiatry Fellow, Baylor College of Medicine

Target Audience: This activity was developed to meet the needs of psychiatric clinicians (medical doctors, psychiatric nurses).

Webinar description: Fentanyl is the leading cause of opioid overdoses during the last couple of years, and these overdoses are not prevented by methadone, buprenorphine or naltrexone treatment. However, a vaccine against fentanyl has been able to block fentanyl’s analgesic, reinforcing and respiratory depressant effects in animal models. This vaccine is moving toward FDA approval to be tested in humans.

Educational objectives:

  • Identify the extent and greatest geographic concentration of fentanyl overdoses and abuse in the current USA opioid epidemic.
  • Define how and why current treatments with naltrexone, methadone and buprenorphine are ineffective for fentanyl abuse.
  • Identify the mechanism of action for fentanyl vaccines in preventing overdoses and abuse through the production of anti-fentanyl antibodies.

Accreditation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation:
American Psychiatric Association (APA) designates this live activity for a maximum of 1 (one) AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

May
29
Wed
Webinar: Evidence-Based Strategies for Preventing Opioid Overdose @ Webinar
May 29 @ 12:00 pm – 1:30 pm
In September 2018, the Centers for Disease Control and Prevention (CDC) released “Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States.” On behalf of the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention and the Center for Faith and Opportunity Initiatives at the U.S. Department of Health and Human Services, we invite you to join us for a discussion on implementing these strategies for preventing opioid overdose in local communities. Community level presenters engaged in programs for harm reduction, treatment initiation and provider education will discuss their work and efforts to successfully implement their program.

Webinar: Evidence-Based Strategies for Preventing Opioid Overdose

When: May 29, 2019 from 12:00-1:30PM EDT

Call-in Access: 1-929-205-6099

Webinar ID: 226-961-046

 

Presenters:

Amber Robinson, PhD, Centers for Disease Control and Prevention, GA

Alice Bell, LCSW, Prevention Point Pittsburgh, PA

Haley Coles, Sonoran Prevention Works, AZ

Nick Jensen, MPA, Shot in the Dark and Sonoran Prevention Works, AZ

Sarah Wakeman, MD, Mass General Hospital, MA

May
30
Thu
Overdose Prevention Training – Public Event @ The Bridge Downeast
May 30 @ 5:30 pm – 7:30 pm

The Bridge Downeast, Carteret County Health Department, and Carteret County Emergency Services host:

Overdose Prevention Training

Where: The Bridge Downeast, 1344 Island Road, Harkers Island
When: Thursday, May 30th
Time: 5:30pm
Participants will learn about the signs and symptoms of opioid overdose; where to access naloxone and how to administer naloxone in the event of an overdose; and community resources for opioid addiction recovery. Additionally, one free Naloxone kit will be given out per Carteret County resident household, while supplies last.
Jun
1
Sat
Treating Pain Safer: One Hour Online Course for Safe Opioid Prescribing – AVAILABLE NOW through March 15, 2021! @ Webinar
Jun 1 @ 12:00 am – 12:00 am

Treating Pain Safer: One Hour Online Course for Safe Opioid Prescribing

Description:
Literature has shown that prescribers receive little education on the treatment of pain resulting in less effective pain treatment with worse outcomes. Participants will learn the evidence-based analysis of the relative effectiveness of medications and their side effects, recommendations on how to improve treatment of acute and chronic pain and recognizing substance use/opioid use disorders. Participants in this online educational activity must pass a posttest for successful completion. This course will focus on acute pain treatments/prescribing that can decrease the likelihood of long-term use.

As of July 1, 2017 all physicians (other than residents), physician assistants, nurse practitioners, podiatrists, and dentists who prescribe controlled substances must satisfy the controlled-substance prescribing CE requirement as set forth by their NC professional boards. Requirements vary by discipline and board. Prescribers will turn in controlled substance CE credits when they renew licensure.

Course Objectives:
1. Describe the impact of the opioid crisis
2. Identify the CDC guidelines for prescribing opioids for acute pain and the STOP Act
3. Discuss opioid alternatives and office policies for safe opioid prescribing

Jun
3
Mon
Opioid and Heroin Abuse Among Our Veterans – Online Course
Jun 3 @ 5:00 pm – 5:30 pm

Description: This 30-minute webinar’s purpose is to discuss how the veteran population is susceptible to the dangers of prescription opioid drug abuse.

Objectives: Discuss how opioid and heroin abuse is affecting the veteran population

Speaker: Patty L Collins, MAEd, BSN, RN, Director of Nursing CPD and Student Training

Audience: The target audience will include physicians, physician assistants, nurse practitioners, nurses, dentists, pharmacists, EMS, law enforcement, mental health professionals, substance abuse counselors, health educators, and others interested in this subject.

Available Credits: AMA PRA Category 1 Credit 0.50, CEU 1.00, ACPE 0.50, CNE Contact Hours 0.50, NCBPTE Contact Hours 0.50

Event Fees: $10.00

Opioids in the Elderly: Trends and New Guidelines – Online Course
Jun 3 @ 5:00 pm – 6:00 pm

Description:

This 1-hour webinar’s purpose is to discuss how the elderly population is susceptible to the dangers of prescription opioid drug abuse.

Objectives:

  • Discuss recent trends in opioid prescribing and prescription opioid misuse in the United States
  • Understand age-related changes that affect pain management
  • Describe the new opioid guidelines

Speaker:

  • Jennifer Gabbard, MD

Audience:

The target audience will include physicians, physician assistants, nurse practitioners, nurses, dentists, pharmacists, EMS, law enforcement, mental health professionals, substance abuse counselors, health educators, and others interested in this subject.

Available Credits:

  • AMA PRA Category 1 Credit 1.00
  • CEU 1.00
  • ACPE 1.00
  • CNE Contact Hours 1.00
  • NCBPTE Contact Hours 1.00

Event Fees: $10.00

Jun
4
Tue
Train-the-Trainer PCSS MAT Waiver Training @ MAHEC
Jun 4 – Jun 5 all-day

Description

Prescriber champions are joining forces with MAHEC to engage in collective impact to resolve the opioid crisis. MAHEC is providing a training for prescribers at residency & training programs such as NP and PA schools to support the incorporation of MAT waiver training into their curriculum. As a first step to help champions become waiver trainers, MAHEC is offering a 2-day experiential train the trainer event. In addition, participants will learn trauma informed care and resiliency informed care models with a health equity approach to treatment and prevention.

Target Audience

Providers, APP’s, Prescribers

Objectives

  • Define how to teach the MAT Waiver Eligibility Training (Live Session)
  • Utilize adult learning strategies in implementing and facilitating MAT presentations
  • Analyze strategies to incorporate MAT into curriculum ongoing
  • Identify workforce and knowledge gaps and utilize implementation science to bridge them
  • Describe strategies for implementing behavioral health models such as trauma and resiliency informed care in MAT
  • Review best practices and lessons learned from MAHEC’s integrated team clinics in FM and OB/GYN
  • Analyze ways to adapt the MAT policies and procedures toolkit to your residency/training program

REGISTER

 

Jun
8
Sat
Waiver Training Online PCSS Office-Based Treatment for Opioid Use Disorders Webinar @ Live Webcast
Jun 8 @ 8:00 am – 12:15 pm

As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study.An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine. 

Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

For More Information and FREE training and educational resources on Medication Assisted Treatment –Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT) visit www.pcssnow.org.

PCSS is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with the: American Osteopathic Academy of Addiction Medicine (AOAAM); Addiction Technology Transfer Center (ATTC); American Academy of Family Physicians (AAFP); American Academy of Neurology (AAN); American Academy of Pain Medicine (AAPM); American Academy of Pediatrics (AAP); American College of Emergency Physicians (ACEP); American College of Physicians (ACP); American Dental Association (ADA); American Medical Association (AMA); American Psychiatric Association (APA); American Psychiatric Nurses Association (APNA); American Society of Addiction Medicine (ASAM); American Society for Pain Management Nursing (ASPMN); Association for Medical Education and Research in Substance Abuse (AMERSA); International Nurses Society on Addictions (IntNSA); National Association of Community Health Centers (NACHC); National Association of Drug Court Professionals (NADCP), and the Southeast Consortium for Substance Abuse Training (SECSAT). 

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Jun
11
Tue
Opioid Misuse and Overdose Prevention Summit @ McKimmon Center
Jun 11 @ 9:00 am – Jun 12 @ 3:30 pm
Jun
15
Sat
Waiver Training – Duke Physician Assistant Program 8 Hour MAT Waiver Training @ JB Duke Hotel
Jun 15 @ 7:00 am – 5:15 pm

Duke Physician Assistant Program MAT Waiver Training

The “Drug Addiction Treatment Act of 2000” created the opportunity to expand treatment for opioid use disorder into the mainstream of medical practice, increase the number of persons treated, and have an important positive public health impact. The legislation specifies several ways in which physicians can be considered qualified to prescribe and dispense buprenorphine in their offices for the treatment of opioid use disorder. The completion of this training fulfills the requirement prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid use disorder.

The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in an office-based setting. The goal of this training is to acquire the knowledge and skills needed to provide optimal care to opioid use disorder patients by providing:

1) an overview of opioid use disorder
2) the efficacy and safety of buprenorphine
3) process of patient selection
4) clinical use of buprenorphine
5) nonpharmacological interventions
6) medical psychiatric conditions in opioid use disorder patients
7) office procedures
8) special treatment population

In total this eight hour training will include eight separate modules and four case studies. The speaker will be presenting for six hours. The remaining two hours is broken up over four case studies.

Designated by the DHHS, this training meets the eight-hour requirement and is designed for physicians to dispense buprenorphine in office practice for treatment of opioid use disorder. Participation in this training will provide physicians with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting. This training is designed for physicians and other primary care providers who are likely to treat opioid dependent persons in their practice, such as those in family practice, general internal medicine, psychiatry, pediatrics, adolescent medicine specialists, and Opioid Treatment Programs.

Target Audience

Residents, faculty, and other interested prescribers

Objectives

  • Review addiction identification and evidence-based treatments
  • Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients
  • Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient
  • Explain the process of buprenorphine induction as well as stabilization and maintenance
  • Discuss other approved antagonist and agonist medications to treat OUD
  • Discuss basic office protocols including medical record documentation and confidentially
  • Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD
  • Apply for a MAT Waiver Training Certificate to begin treating patients with OUD

Faculty

  • James W. Finch, MD FASAM
7:00am-8:00am Registration and Sign-In
8:00am-8:30am Overview
8:30am-9:00am Neurobiology
9:00am-10:00am Patient Evaluation
10:00am-10:45am Small Group / Case #1:  ADDICTED SCHOOL TEACHER

***PLEASE GO TO YOUR ASSIGNED BREAKOUT SECTION***

10:45am-11:00am BREAK
11:00am-11:45am Pharmacology
11:45am-12:15pm Specialty Topics
12:15pm-1:15pm LUNCH
1:15pm-2:00pm Medication Assisted Treatment (MAT) and Urine Drug Testing
2:00pm-2:45pm Small Group / Case #2:  ADDICTION AND DEPRESSION

***PLEASE GO TO YOUR ASSIGNED BREAKOUT SECTION***

2:45pm-3:25pm Evidence-Based Counseling
3:25pm-4:00pm Clinical Management
4:00pm-4:45pm Small Group / Case #3:  SETTING TREATMENT GOALS

Small Group / Case #4:  COCAINE ABUSE PROBLEM

***PLEASE GO TO YOUR ASSIGNED BREAKOUT SECTION***

4:45pm-5:15pm Completion of DEA Waiver; Questions and Answers; Evaluations
5:15pm-5:30pm Sign-Out

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA.  The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Jun
19
Wed
Adopting Best Practices in Substance Abuse Treatment: An Ongoing Teaching Case Conference Series @ William F Andrews Center
Jun 19 @ 10:30 am – 12:00 pm

Program Description: In this time of major systems change, addiction treatment professionals are challenged to treat increasingly complex alcohol and other drug use disorders with a greater emphasis on evidence-based outcomes and cost effectiveness. At the same time there have been significant advances in our understanding of the biological and environmental underpinnings of addictive disease which has informed emerging treatment best practices. While a number of evidence based behavioral and medication assisted practices have been developed to respond to the science, the gap between research and practice has been highlighted by the Institute of Medicine (1998). In an effort to bridge this gap, there is a growing effort within the field of addictions treatment to better integrate research with practice by implementing science based practices. These specific practices are described in NIDA’s Priniciples of Drug Addiction Treatment : A Research Based Guide (2008) as well as in the findings from the Conference on Approaches For Combating the Troublesome Use of Substances (CACTUS) as published in Rethinking Substance Abuse by William R. Miller and Kathleen M. Carroll (2008). This series is also focused on introducing participants to evidence based treatment models included in the current National Registry of Evidence Based Programs Practices (SAMHSA). These EBPs include Motivational Interviewing, Motivational Incentives, Seeking Safety, Cognitive Based Therapies and Mindfulness based interventions. Discussions will focus on ways that practitioners can apply these practices and evidence based models to current clinical situations.

Method: This teaching case conference series uses a traditional case study and facilitated learning collaborative method to assist participants to identify, learn and apply best practices and evidence based models within the context of actual cases. Participants will be expected to come prepared each session with cases that present special challenges as well as opportunities for learning. The goal of these conferences will be to identify appropriate best practices and to find ways in which specific evidence based treatments can be used to incorporate the use of evidence based treatments.

This teaching case conference series is also intended to promote collaboration among treatment providers in an effort to facilitate cross referrals, promote a regional recovery oriented system of care and integrated care approaches. The series will also serve as a vehicle for disseminating information about new research findings as well as available professional development and community service resources. Finally, these sessions will be facilitated in a manner to promote collegial support and enhance workforce morale and retention.

See brochure for speaker information.

Objectives

  • Present cases that provide an opportunity for shared learning.
  • Learn and discuss best practices and evidence based treatments that can be applied in the real world.
  • Identify opportunities for further training in evidence based practices.
  • Facilitate referrals and system of care development.
  • Review and discuss research based findings and perspectives.
  • Improve workforce morale and retention.
Jun
24
Mon
Waiver Training Online PCSS Office-Based Treatment for Opioid Use Disorders Webinar @ Live Webcast
Jun 24 @ 5:00 pm – 9:15 pm

As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine. 

Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

CONTINUING MEDICAL EDUCATION: This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

For More Information and FREE training and educational resources on Medication Assisted Treatment –Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT) visit www.pcssnow.org.

PCSS is a collaborative effort led by the American Academy of Addiction Psychiatry (AAAP) in partnership with the: American Osteopathic Academy of Addiction Medicine (AOAAM); Addiction Technology Transfer Center (ATTC); American Academy of Family Physicians (AAFP); American Academy of Neurology (AAN); American Academy of Pain Medicine (AAPM); American Academy of Pediatrics (AAP); American College of Emergency Physicians (ACEP); American College of Physicians (ACP); American Dental Association (ADA); American Medical Association (AMA); American Psychiatric Association (APA); American Psychiatric Nurses Association (APNA); American Society of Addiction Medicine (ASAM); American Society for Pain Management Nursing (ASPMN); Association for Medical Education and Research in Substance Abuse (AMERSA); International Nurses Society on Addictions (IntNSA); National Association of Community Health Centers (NACHC); National Association of Drug Court Professionals (NADCP), and the Southeast Consortium for Substance Abuse Training (SECSAT). 

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Jun
27
Thu
Waiver Related Training Recovery Within Reach: Building Team Expertise in Office-Based Opioid Treatment (OBOT) @ MAHEC
Jun 27 @ 3:45 pm – 8:30 pm

Description

Opioid addiction is a chronic, relapsing brain disease that affects millions of Americans and produces a tremendous burden on the healthcare system. In 2002, U.S. physicians gained the opportunity to treat opioid-addicted patients with buprenorphine in primary care settings, commonly referred to as office-based opioid treatment (OBOT). OBOT has been shown to be effective in primary care settings and impacts public health through the reduction of opioid use, opioid overdose mortality and transmission of infectious diseases. However, it remains underutilized.

One consistently cited barrier preventing OBOT expansion is lack of adequate clinical support given the additional needs for patient monitoring. Successful medication-assisted treatment (MAT) requires a team-based approach just like treatment for other chronic diseases. In addition, treatment is more effective when providers can use a trauma-informed and gender-responsive treatment plan.

The goal of this companion program to the AAAP Clinical Support System: Buprenorphine Office-Based Treatment for Opioid Use Disorders (The “Half and Half” Course) is to increase the comfort level and expertise of the healthcare team by outlining a team approach, trauma-informed interventions, gender-responsive care, and recommendations for implementation of buprenorphine OBOT.

Target Audience

Nurses, mental health professionals including substance abuse counselors, social workers, psychologists, marriage and family therapists, school counselors, practice managers, program administrators, medical assistants, care managers and coordinators and other professionals interested in this subject.

Objectives

  • Describe the presented framework of office-based opioid treatment (OBOT) including practice changes, medications used, psychosocial services and integration/coordination components
  • Utilize evidence-based interventions that are trauma-informed and gender-responsive to treat persons with substance use disorders
  • Define the roles of an effective practice team, including primary care and behavioral health clinicians, working together with patients and families, and using a systematic and cost-effective approach to provide patient-centered care for opioid and other substance use disorders
  • Increase medical and behavioral health professionals’ receptivity and capability to work collaboratively as they evaluate and manage opioid and other substance use disorders using SBIRT (screening, brief intervention and referral to treatment)
  • List key components of evidence-based and effective OBOT
Waiver Training Providers’ Clinical Support System – Buprenorphine Office Based Treatment for Opioid Use Disorders The “Half and Half” Course @ MAHEC
Jun 27 @ 4:00 pm – 8:45 pm

Description

Opioid dependence is epidemic in the United States. While progress has been made in training providers, the gap in providing effective treatment of opioid use disorders continues to widen, moving beyond heroin addicted individuals to a much larger and diverse segment of the population. This increase is predominantly due to an alarming increase in addiction to prescription opioid analgesic medications. Buprenorphine, the most recent addition to the pharmacotherapies available to treat opioid dependence, is novel among the opioid pharmacotherapies because of its partial agonist properties. It has been placed on Schedule III and is available by prescription from a physician’s office-based practice.

Recognizing the impact of this addiction, as well as learning how to treat opioid use disorders, are important steps in combating this ever growing medical problem. To obtain the waiver to prescribe, providers are required to take specialized training. PCSS-MAT uses the Half-and-Half format (first, 4.25 hours of face-to-face training with an instructor, followed by 3.75 hours of on-your-own-training that must be completed along with a post test). This training meets the requirements for physicians; however additional training is required for advanced practice providers. The training focuses on specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment. Once the waiver training is completed in full, participants will receive a CME certificate of attendance from AAAP.

This program includes up to 2.0 hours of controlled substances content. Per NCAC rules: As of July 1, 2017, all physicians (other than residents), physician assistants, nurse practitioners, podiatrists, and dentists who prescribe controlled substances must satisfy the controlled-substance prescribing CE requirements as set forth by their licensing boards. Requirements vary by discipline and board.

Target Audience

The program is recommended for prescribers in primary care, emergency medicine, pain management, psychiatric, HIV, and addiction medicine. (Not a prescriber? CLICK HERE)

Objectives

  • Review addiction treatment in office-based practices
  • Discuss the pharmacological treatments of opioid use disorder
  • Determine what medical record documentation must be followed
  • Discuss the process of buprenorphine induction as well as stabilization and maintenance techniques
  • Describe how to take a patient history and evaluation
  • Review safety concerns and drug interactions